Cargando…
Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear
Rapid uptake previously demonstrated by intradermal (ID) drug administration indicates compound delivery within the dermis may have clinical and pharmacological advantages for certain drug therapies. This study is the first clinical trial to evaluate continuous microneedle-based drug infusion, devic...
Autores principales: | Rini, Christopher James, McVey, Elaine, Sutter, Diane, Keith, Stephen, Kurth, Heinz-Joerg, Nosek, Leszek, Kapitza, Christoph, Rebrin, Kerstin, Hirsch, Laurence, Pettis, Ronald J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529466/ https://www.ncbi.nlm.nih.gov/pubmed/26037035 http://dx.doi.org/10.1007/s13346-015-0239-x |
Ejemplares similares
-
Changes in Basal Insulin Infusion Rates With Subcutaneous Insulin Infusion: Time until a change in metabolic effect is induced in patients with type 1 diabetes
por: Heinemann, Lutz, et al.
Publicado: (2009) -
Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022) -
Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial
por: Heise, Tim, et al.
Publicado: (2016) -
Continuous subcutaneous insulin infusion: practical issues
por: Saboo, Banshi D., et al.
Publicado: (2012) -
Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
por: Bode, Bruce W., et al.
Publicado: (2017)